MENU
TAK
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

TAK stock forecast, quote, news & analysis

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for TAK with price predictions
Nov 10, 2026

Aroon Indicator for TAK shows an upward move is likely

TAK's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 283 similar instances where the Aroon Indicator showed a similar pattern. In 157 of the 283 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 55%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on TAK as a result. In 46 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 48%.

The Moving Average Convergence Divergence (MACD) for TAK just turned positive on October 14, 2026. Looking at past instances where TAK's MACD turned positive, the stock continued to rise in 23 of 43 cases over the following month. The odds of a continued upward trend are 53%.

TAK moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in 157 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.

Bearish Trend Analysis

The 10-day RSI Indicator for TAK moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 15 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 39%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 59 cases where TAK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 54%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.

TAK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.009) is normal, around the industry mean (6.379). P/E Ratio (-0.402) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.425) is also within normal values, averaging (2.202). Dividend Yield (0.056) settles around the average of (0.062) among similar stocks. P/S Ratio (1.968) is also within normal values, averaging (183.387).

The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

TAK paid dividends on July 08, 2024

Takeda Pharmaceutical Company Limited TAK Stock Dividends
А dividend of $0.29 per share was paid with a record date of July 08, 2024, and an ex-dividend date of March 27, 2024. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 10%. XERS experienced the highest price growth at 53%, while AKAN experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 3 (-100 ... +100)
Aroon Indicator for TAK shows an upward move is likely